
Novavax awaits FDA decision on whether its next COVID shot can be offered in US
By Michael Erman (Reuters) – Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this year, the company said. Novavax’s updated vaccine targets a variant called JN.1, which is in line…